Clearing Uncertainty in Pharma and Biotech: Securing Valuation Legitimacy Through Disclosure Reform
Amid global monetary policy uncertainty and external risks, the pharmaceutical and biotech sector—characterized largely as growth stocks—has shown a sideways trend, with its upside limited in the absence of a clear momentum driver. In particular, declining investor confidence in clinical results and technology licensing agreements has been identified as a key factor in the sector’s overall undervalued valuations, prompting growing calls for institutional mechanisms to protect investors.
The authorities’ recently announced disclosure reform plan centers on specifying key information related to corporate value from the listing stage to technology transfers and ad hoc disclosures, while making it mandatory to provide explanations of technical terms. Even for undisclosed technology transfer contracts, counterparties must now disclose at least their minimum business capabilities, thereby improving reliability. Effectiveness has also been ensured by linking compliance with the guidelines to requests for corrections. As a result, a stable inflow of supply and demand is expected, particularly among biotech firms that have curbed excessive speculation and improved their fundamentals.
Meanwhile, interest in stock-backed loans, known as “stock loans,” is steadily rising. Investors seeking not to miss rare investment opportunities are turning to stock loan products, which allow them to access additional funds for stock purchases.
Another advantage of stock loans is that even if borrowers face forced liquidation risks—due to sudden stock price drops while using margin/credit services—they can simply switch to a stock loan without providing additional collateral or selling their holdings, and then wait for a rebound in prices.
◆ All New Stock Loan introduces new products at industry-low annual interest rates of just 5%!
All New Stock Loan has launched a securities credit-linked product, available at the industry’s lowest annual interest rate in the 5% range, enabling any investor to take advantage of stock loans affordably. This product can be used for both direct stock purchases and refinancing margin/credit balances at securities firms, regardless of one’s credit rating, with up to 4x leverage including personal capital. Investors using alternative exchanges (NXT) can also access this service.
For more information on All New Stock Loan, investors can contact the customer service center (☎1599-8666) at any time—regardless of loan approval status—for convenient consultations with a specialist.
○ Launch of securities credit-linked products at an industry-low annual interest rate in the 5% range!
○ ETF trading available
○ Up to 4x leverage for stock investment (including personal capital)!
○ Immediate same-day refinancing for securities margin/credit accounts!
○ Trading via Alternative Exchange (NXT) is supported
○ Stocks previously difficult to purchase with securities firm credit or stock loans now eligible!
* All New Stock Loan Customer Service Center: 1599-8666
Direct link: https://allnewstockloan.co.kr
Hanmi Semiconductor, LS ELECTRIC, Rainbow Robotics, Ecopro, Hanwha Aerospace
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
※ The above content is unrelated to The Asia Business Daily’s editorial direction, and all responsibility rests with the information provider.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.